

# Evaluasi Penatalaksanaan Farmakoterapi Pasien COVID-19 di Puskesmas Pasar Rebo Periode Januari-Maret 2022 = Evaluation of Pharmacotherapy Management of COVID-19 Patients at Pasar Rebo Health Center January-March 2022 Period

Yoga Amarta, author

Deskripsi Lengkap: <https://lib.ui.ac.id/detail?id=9999920526602&lokasi=lokal>

---

## Abstrak

Corona Virus Disease 2019 (COVID-19) adalah penyakit menular yang disebabkan oleh virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Shereen, Khan, Kazmi, Bashi, & Siddique, 2020). Pusat Kesehatan Masyarakat adalah fasilitas pelayanan kesehatan yang menyelenggarakan upaya Kesehatan masyarakat dan upaya Kesehatan perseorangan tingkat pertama, dengan lebih mengutamakan upaya promotive dan preventif, untuk mencapai derajat Kesehatan masyarakat yang setinggi-tingginya di wilayah kerjanya (Kementerian Kesehatan Republik Indonesia, 2014). Tatalaksana pengobatan pasien COVID-19 di Indonesia mengacu pada Pedoman Tatalaksana COVID-19 edisi 4 yang diterbitkan pada bulan Januari 2022. Puskesmas Ps. Rebo memiliki 320 pasien COVID-19 pada bulan Januari hingga Maret 2022. Penelitian ini dilakukan untuk mendeskripsikan penggunaan antimikroba, mengidentifikasi masalah yang terjadi dalam alur penanganan pasien COVID-19, dan mengevaluasi penatalaksanaan pasien COVID-19 di Puskesmas Ps. Rebo. Berdasarkan penelitian, dapat disimpulkan bahwa 1. Antimikroba yang digunakan pada pasien COVID-19 di Puskesmas Ps. Rebo adalah favipiravir (80,3%); azitromisin (9,8%); oseltamivir (0,8%); ciprofloxacin (0,8%); amoxicillin (0,8%).

..... Corona Virus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (Shereen, Khan, Kazmi, Bashi, & Siddique, 2020).

Community Health Centers are health care facilities which organizes community health efforts and individual health efforts at the first level, by prioritizing promotive and preventive efforts, to achieve the highest degree of public health in their working area (Ministry of Health of the Republic of Indonesia, 2014). The management of the treatment of COVID-19 patients in Indonesia refers to the 4th edition of the Guidelines for the Management of COVID-19 which was published in January 2022. The Ps. Rebo had 320 COVID-19 patients from January to March 2022. This research was conducted to describe the use of antimicrobials, identify problems that occur in the flow of handling COVID-19 patients, and evaluate the management of COVID-19 patients at the Ps Health Center. Rebo. Based on the research, it can be concluded that 1. Antimicrobials used on COVID-19 patients at the Ps. Rebo is favipiravir (80.3%); azithromycin (9.8%); oseltamivir (0.8%); ciprofloxacin (0.8%); amoxicillin (0.8%).